

NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...
Dec 1, 2021
1,001


NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...
Aug 6, 2021
237


NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...
Aug 6, 2021
767


Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...
Jun 12, 2021
159


NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose...
Dec 18, 2020
159


NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...
Dec 17, 2020
699


NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
IsKPd - IFM2018-03 NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in...
Dec 10, 2020
211


NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
EMN26 NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients Iberdomide (Cc220) Maintenance After...
Dec 9, 2020
273


NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...
Dec 27, 2019
575


NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM
Study CC-99712-MM-001 This is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical...
Dec 19, 2019
557


NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...
Dec 13, 2019
202


NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...
Dec 11, 2019
757


NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...
Dec 6, 2019
34


NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...
Dec 31, 2018
221


NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Study CC-93269-MM-001...
Dec 23, 2018
279


NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...
Dec 19, 2018
521


NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...
Dec 16, 2018
578


NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...
Dec 13, 2018
53


NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI
Myeloma XI The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide...
Dec 7, 2018
399